

## Due Diligence Report: CEO Calls Meeting, Shares Skyrocket 48%

### Summary

Harvard Apparatus Regenerative Technology, Inc., incorporated on May 3, 2012, is a clinical-stage biotechnology company making regenerated organs for transplant. The Company's product, the HART-Trachea, is intended to be used to restore the structure and/or function of a severely damaged trachea (windpipe). The HART-Trachea comprises the patient's own bone marrow cells seeded on the Company's InBreath porous plastic scaffold in its InBreath organ bioreactor. Its HART-Trachea addresses both of the challenges to trachea transplant, such as the shortage of suitable donor tracheas and the risk and expense of lifelong anti-rejection drug therapy. The Company has received orphan drug designation from the United States Food and Drug Administration (FDA) for the HART-Trachea in the United States market. The Company is engaged in pre-clinical development of its HART-Trachea. As of December 31, 2014, the HART-Trachea has been implanted in five adult human patients. Average survival among the three of these patients who have died to date has been 22 months. Of the three patients who have died, none of them have died because of a failure of its scaffold. Two of the patients are still alive. Of those two patients, one is at approximately 9 months and the other is at approximately two and one half years from being first implanted.

Harvard Apparatus Regenerative Technology Inc. has a current market capitalization of \$29.60 M with 13.45 M outstanding shares. Its daily average volume traded is 1.76 M shares.

### Key Indicators (Q3 2015)

Shares Outstanding	13.45 M
Revenue	0.04 M
Gross Profit	0.02 M
Net Loss (basic/diluted)	-2.29 M
Cash and Short-term Inv	8.20 M
Total Debt	Nil

### Performance (6 months)



### Recent News and Analysis:

The company recently announced it has received written notification from The NASDAQ Stock Market that it has regained compliance with the minimum bid price requirements. The letter noted that as a result of the closing bid price of HART's common stock having exceeded \$1.00 per share for more than ten consecutive business days, the company has regained compliance and the matter is now closed. HART's CEO, Jim McGorry, commented, "Maintaining our NASDAQ listing is fundamental to our

corporate strategy. We are gratified by the investment community's response to our recent progress, including the positive animal research results on HART's second generation (Gen2) bioengineered esophageal, tracheal and bronchial implants." Mr. McGorry continued, "Going forward, our development plan is focused on getting our technology back into humans on a compassionate use basis and filing our first clinical trial application with the FDA during 2016. We are confident that we will meet these goals given the results of our recent studies using our Gen2 technology across all three applications, our strong scientific team and our collaborations with translational partners. We have initiated confirmatory large-animal studies of our Gen2 implants with Mayo Clinic. The study design has been completed, prerequisite tests are underway, and we expect the animal surgeries to occur in December."

In addition, CEO Jim McGorry is set to hold a special investor event on December 1 in Los Angeles, California. This apparently has given investors reason for hope, as the stock moved up nearly 48% on Monday, reaching a volume of 18.48 M shares; versus a daily average volume of 1.76 M shares. Shareholders are hoping for steady progress to be revealed by the company whose main line of business involves the development of bioengineered organ implants for transplantation.

### **Conclusions:**

Investors reacted favorably to the recent announcements made by the company. Shares of HART skyrocketed nearly 82% in the last five days and appear to be moving higher in afterhours trading. This is certainly a reversal of trends compared to the past 52 weeks and is expected moving forward given the CEO announces favorable news during the conference on Dec 1, 2015. Despite what the CEO announces, the Company's products are gaining traction and should lead to profitability in the near future.

## Sources:

1. <http://stockcharts.com/h-sc/ui?s=HART&p=D&b=5&g=0&id=p34205659772>
2. <http://investor.harvardapparatusregen.com>
3. [http://www.google.ca/finance?q=NASDAQ%3AHART&fstype=ii&hl=en&gl=ca&ei=QOhcVon\\_NtL\\_jAHRsJWoBg](http://www.google.ca/finance?q=NASDAQ%3AHART&fstype=ii&hl=en&gl=ca&ei=QOhcVon_NtL_jAHRsJWoBg)
4. <http://ir.net/stock-news/19753/harvard-apparatus-regenerative-tech-inc-hart-investor-presentation-coming-next-week-stock-jumps/>
5. <http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=HART.O#6zLbGzSkcBEjqXde.97>
6. <http://www.benzinga.com/pressreleases/15/11/n6009709/hart-regains-compliance-with-nasdaq-minimum-bid-price-listing-rule>
- 7.

## Risk Factors

An investment in the common stock of the company is subject to a number of risks. The information below contains latest filings and risk factors that should be considered by all investors. Investors should carefully consider the risk factors set out below and consider all other information contained herein, and in the company's SEC filings, before making an investment decision. We assume no obligation to update or revise any such forward looking statements to reflect events or circumstances that occur after such statements are made. A complete list of filings including the risk factors for the company can be found here: <http://www.sec.gov/cgi-bin/browse-edgar?CIK=prgn&Find=Search&owner=exclude&action=getcompany>

Disclosure: I, Robert Borowski, research analyst have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions and I have no business relationship with any company whose stock is mentioned in the article.

The information contained herein is not intended to be investment advice and does not constitute any form of invitation or inducement by Robert Borowski to engage in investment activity. Neither the information nor any opinion expressed constitutes a solicitation for the purchase or sale of any security. Securities, financial instruments, strategies, or commentary mentioned herein may not be suitable for all investors and this material is not intended for any specific investor and does not take into account an investor's particular investment objectives, financial situations or needs. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only current as of the stated date of their issue. Prices, values, or income from any securities or investments mentioned in this report may fluctuate, and an

investor may, upon selling an investment lose a portion of, or the entire principal amount invested. Past performance is no guarantee of future results. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.

#### FORWARD-LOOKING STATEMENT

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

#### COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Robert Borowski. An outsourced research services provider represented by Robert Borowski, provided Broad Street Alerts this article or report. However, we are only human and may make mistakes. If you notice any errors or omissions, please notify us below. Broad Street Alerts is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Robert Borowski. All parties responsible for the creation and dissemination of this report do not engage in high frequency trading.

#### NO WARRANTY OR LIABILITY ASSUMED

Broad Street Alerts has not been compensated for the creation or dissemination of this report. Broad Street Alerts is not responsible for any error, mistake or shortcoming which may be occasioned at the time of printing of this document. Broad Street Alerts does not hold any positions in profiled company(s). No liability is accepted by Broad Street Alerts whatsoever for any direct, indirect or consequential loss arising from the use of this document. Broad Street Alerts expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Broad Street Alerts does not guarantee the accuracy, timeliness, completeness or correct sequencing of the

information, or warrant any results from use of the information. The included information is subject to change without notice.

Broad Street Alerts is the party responsible for hosting the full analyst report. Broad Street Alerts has compensated Robert Borowski seventy five dollars for the right to disseminate this report. Information in this report is fact checked and produced on a best efforts basis by Robert Borowski.